Related Experiment Video
Updated: Oct 24, 2025

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
[What do we Mean by "Ideal" Blood Pressure Control?]
O D Ostroumova1, A I Kochetkov2, N A Arablincky3
1Russian Medical Academy of Continuous Professional Education, Moscow; I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow.
Insights
High blood pressure variability (BPV) is a significant risk factor for cardiovascular issues. The fixed-dose combination amlodipine/perindopril effectively reduces BPV and blood pressure, improving patient prognosis.
Area of Science:
- Cardiology
- Hypertension Management
Background:
- Arterial hypertension (AH) is a major risk factor for severe cardiovascular and cerebrovascular diseases.
- Increased blood pressure variability (BPV) is recognized as a novel, independent risk factor for these complications.
Purpose of the Study:
- To evaluate the efficacy of fixed-dose combination (FC) amlodipine/perindopril in reducing blood pressure and BPV.
- To assess the clinical significance of managing BPV in patients with AH.
Main Methods:
- Review of clinical studies and real-life data on amlodipine/perindopril FC.
- Analysis of BPV reduction across different timescales (visit-to-visit, day-to-day, 24-hour).
Main Results:
- Amlodipine/perindopril FC demonstrated significant reductions in all measured types of BPV.
- The combination therapy showed high antihypertensive efficacy in real-world clinical practice.
- Evidence supports the benefit of reducing BPV for improved patient outcomes.
Conclusions:
- Fixed-dose combination amlodipine/perindopril is a first-line treatment option for AH.
- This FC offers a dual benefit of lowering blood pressure and decreasing BPV.
- Amlodipine/perindopril FC is recommended for a wide range of AH patients to enhance prognosis.
Abstract:
Arterial hypertension (AH) is one of the most important risk factors for development of myocardial infarction, chronic heart failure, stroke, cognitive disorders and dementia, and chronic kidney disease. Currently, special attention is paid to increased blood pressure variability (BPV) as a new risk factor for development of cardiovascular and cerebrovascular complications. The available evidence-based body of clinical studies demonstrates the importance of reducing not only the blood pressure itself but also the increased BPV to provide significant improvement of the prognosis and limits the risk of complications. This notion has been validated in consensus documents on the management of patients with AH. Among antihypertensive drugs, the fixed-dose combination (FC) amlodipine/perindopril has demonstrated a unique capability for reducing all types of BPV (visit-to-visit, day-to-day, during 24 h). According to current clinical guidelines, this combination belongs to first-line FCs indicated for most patients with AH. A distinctive feature of the FC amlodipine/perindopril is numerous data from real-life clinical practice, which support both its high antihypertensive efficacy and the ability to decrease high BPV. Therefore, the FC amlodipine/perindopril can be recommended for a broad range of AH patients to achieve BP control and to improve the prognosis.
More Related Videos
Related Concept Videos
Blood Pressure
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the...
Blood Pressure
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Measurement of Blood Pressure
Errors occurring during blood pressure monitoring
Several factors...

